Pancreatic adenocarcinoma, version 2.2017: Clinical Practice Guidelines in Oncology Journal Article

Authors: Tempero, M. A.; Malafa, M. P.; Al-Hawary, M.; Asbun, H.; Bain, A.; Behrman, S. W.; Benson, A. B. 3rd; Binder, E.; Cardin, D. B.; Cha, C.; Chiorean, E. G.; Chung, V.; Czito, B.; Dillhoff, M.; Dotan, E.; Ferrone, C. R.; Hardacre, J.; Hawkins, W. G.; Herman, J.; Ko, A. H.; Komanduri, S.; Koong, A.; LoConte, N.; Lowy, A. M.; Moravek, C.; Nakakura, E. K.; O'Reilly, E. M.; Obando, J.; Reddy, S.; Scaife, C.; Thayer, S.; Weekes, C. D.; Wolff, R. A.; Wolpin, B. M.; Burns, J.; Darlow, S.
Article Title: Pancreatic adenocarcinoma, version 2.2017: Clinical Practice Guidelines in Oncology
Abstract: Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresect-able disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adeno-carcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection. © JNCCN-Journal of the National Comprehensive Cancer Network.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 15
Issue: 8
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2017-08-01
Start Page: 1028
End Page: 1061
Language: English
DOI: 10.6004/jnccn.2017.0131
PROVIDER: scopus
PUBMED: 28784865
Notes: Review -- Export Date: 5 September 2017 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Eileen O'Reilly
    316 O'Reilly